高级检索
马丽丽, 华宜丹, 韩秀成, 王淇, 宁峻涛, 焦洪涛, 雷瑞鹏, 刘欢. 全球尼帕病毒专利数据挖掘及全景分析[J]. 中国公共卫生, 2022, 38(3): 360-363. DOI: 10.11847/zgggws1132805
引用本文: 马丽丽, 华宜丹, 韩秀成, 王淇, 宁峻涛, 焦洪涛, 雷瑞鹏, 刘欢. 全球尼帕病毒专利数据挖掘及全景分析[J]. 中国公共卫生, 2022, 38(3): 360-363. DOI: 10.11847/zgggws1132805
MA Li-li, HUA Yi-dan, HAN Xiu-cheng, . Data mining and panoramic analysis on global Nipah virus-related patent applications[J]. Chinese Journal of Public Health, 2022, 38(3): 360-363. DOI: 10.11847/zgggws1132805
Citation: MA Li-li, HUA Yi-dan, HAN Xiu-cheng, . Data mining and panoramic analysis on global Nipah virus-related patent applications[J]. Chinese Journal of Public Health, 2022, 38(3): 360-363. DOI: 10.11847/zgggws1132805

全球尼帕病毒专利数据挖掘及全景分析

Data mining and panoramic analysis on global Nipah virus-related patent applications

  • 摘要:
      目的   客观展现尼帕病毒领域的专利研发现状,为我国科技人员开展相关专利申请和相关领域技术研究提供情报参考。
      方法   从科技情报的视角,2002.1.1 — 2020.8.18 Web of Science中的DII数据库中的尼帕病毒相关专利数据为研究对象,利用Derwent Data Abalyzer 9.0工具从整体申请趋势、专利技术领域、主要申请国家及其技术布局、专利保护强度等进行了数据挖掘和全景分析。
      结果   尼帕病毒的专利申请自2002年开始整体呈上升发展趋势,美国、中国、加拿大是该领域的主要专利申请国家,当前的研发热点主要在抗病毒剂、病毒性抗原或抗体制品、DNA重组技术或疫苗研发、病毒检测方法等领域,我国在抗病毒剂或抗病毒药、病毒性抗原或抗体等技术领域欠缺。
      结论   鉴于尼帕病毒的生物安全四级病原特性,美国等国家在尼帕病毒的技术研发和专利申请上在不断加强,我国需在相关领域开展前瞻性研究和生物安全的风险防控。

     

    Abstract:
      Objective   To describe the status of Nipah virus-related patent application around the world and to provide references for relevant patent application and researches in China.
      Methods  Global data on Nipah virus-related patent applications from 2002 up to August 18, 2020 were searched through Derwent Innovations Index of Web of Science. Derwent Data Analyzer 9.0 was adopted to conduct data mining and panoramic analysis on overall trend, technology field and layout, countries of registration, and protection intensity of the declared patents.
      Results  From the year of 2002, the annual number of Nipah virus-related patent applications increased generally. The United States, China and Canada are among the major registration countries of those patent applications. The filed patent applications were mainly for antiviral agent, viral antigen or antibody products, DNA recombination technology, vaccine development, and virus detection method. The number of patent applications for antiviral agents/antivirals and viral antigen/antibody is relatively small in China compared to that in major registration countries.
      Conclusion   The increase in annual number of Nipah virus-related patent applications indicates that technology research and development on the pathogen of biosafety level 4 are enhanced continuously in the United States and other countries and relevant researches need to be promoted in China for Nipah virus-related biosafety and epidemic prevention.

     

/

返回文章
返回